Market Overview:
The global perennial allergic rhinitis drug market is expected to grow at a CAGR of 5.8% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of perennial allergic rhinitis, rising awareness about available treatment options, and growing demand for better-tolerated drugs. The global perennial allergic rhinitis drug market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into APC-3000, asapiprant, bilastine, desloratadine and others. On the basis of application, the market is segmented into clinic setting and hospital setting. The clinic setting segment dominates this market owing to high patient population base for treatment in this sector across all regions studied in this research study. Geographically speaking North America dominates this space with highest revenue share followed by Europe due To high adoption rate Of these drugs In these regions respectively .
Product Definition:
Perennial allergic rhinitis is a long-term (chronic) condition that causes inflammation and irritation in the nose. It is caused by an allergy to something in the environment, such as pollen, dust, or pet dander. Symptoms include sneezing, congestion, a runny nose, and itchy eyes. Perennial allergic rhinitis can be treated with medications called antihistamines or nasal corticosteroids. These medications help to control inflammation and symptoms.
APC-3000:
Allergic rhinitis is a type of chronic inflammation of the nasal passages and olfactory nerves that results in symptoms such as sneezing, itching, congestion, and rhinorrhea. The drug Allerga APC-3000 (amphoteric phosphorothioate) is indicated for the treatment of perennial allergic rhinitis. Perennial Allergic Rhinitis (PAR) has been previously called hay fever or pollinosis.
Asapiprant:
Asapiprant is a non-steroidal anti-inflammatory drug (NSAID) used for the treatment of perennial allergic rhinitis. It works by blocking the release of inflammatory cytokines and histamine from immune cells. Asapiprant was approved by the U.
Application Insights:
Based on application, the market is segmented into clinic, hospital and others. Clinic held the largest share of around 60.0% in 2017 owing to increasing awareness about PPAR among patients and healthcare providers resulting in high usage of anti-rhinitis drugs at clinics.
The hospital segment is expected to witness a lucrative CAGR over the forecast period due to rising prevalence of perennial allergic rhinitis coupled with an increase in number of surgeries performed due to this disease. According to estimates reported by Allergic Living magazine, around 20 million Americans suffer from PAH while approximately 1 out of 10 people globally are estimated to be affected by this condition each year.
Regional Analysis:
North America dominated the global market in 2017. The presence of key players, favorable reimbursement policies, and increasing prevalence of asthma are some factors attributing to its large share. In addition, growing awareness about various treatment options is expected to drive regional growth during the forecast period.
Asia Pacific is anticipated to witness lucrative CAGR over the forecast period owing to rising product approvals and commercialization in countries such as China and Japan. Furthermore, an increase in healthcare expenditure by governments along with a rise in consumer disposable income levels will support regional growth during the same period (2018-2030). Moreover, improving infrastructure coupled with a high population density will further boost revenue generation prospects for these drugs over this timeframe.
Growth Factors:
- Increasing prevalence of allergic rhinitis
- Growing awareness about the benefits of perennial allergic rhinitis drugs
- Rising demand for better treatment options for perennial allergic rhinitis
- Technological advancements in the field of perennial allergic rhinitis drugs
- Growing number of clinical studies on perennial allergic rhinitis
Scope Of The Report
Report Attributes
Report Details
Report Title
Perennial Allergic Rhinitis Drug Market Research Report
By Type
APC-3000, Asapiprant, Bilastine, Desloratadine, Others
By Application
Clinic, Hospital, Others
By Companies
Faes Farma, S.A., Glenmark Pharmaceuticals Ltd., Hisamitsu Pharmaceutical Co., Inc., Merck & Co., Inc., Pfizer Inc., Shionogi & Co., Ltd., VentiRx Pharmaceuticals, Inc., Faes Farma, S.A.
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
216
Number of Tables & Figures
152
Customization Available
Yes, the report can be customized as per your need.
Global Perennial Allergic Rhinitis Drug Market Report Segments:
The global Perennial Allergic Rhinitis Drug market is segmented on the basis of:
Types
APC-3000, Asapiprant, Bilastine, Desloratadine, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Clinic, Hospital, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Faes Farma, S.A.
- Glenmark Pharmaceuticals Ltd.
- Hisamitsu Pharmaceutical Co., Inc.
- Merck & Co., Inc.
- Pfizer Inc.
- Shionogi & Co., Ltd.
- VentiRx Pharmaceuticals, Inc.
- Faes Farma, S.A.
Highlights of The Perennial Allergic Rhinitis Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- APC-3000
- Asapiprant
- Bilastine
- Desloratadine
- Others
- By Application:
- Clinic
- Hospital
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Perennial Allergic Rhinitis Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Perennial allergic rhinitis (PAR) is a type of allergy that lasts for more than 12 months. It's caused by the body's immune system overreacting to pollen, dust, or other allergens. People with PAR often have recurring symptoms such as sneezing, runny nose, and itchy eyes. Some people also experience chest tightness and coughing. PAR can be very frustrating because it can keep you from enjoying activities you love or making everyday tasks difficult.
Some of the major companies in the perennial allergic rhinitis drug market are Faes Farma, S.A., Glenmark Pharmaceuticals Ltd., Hisamitsu Pharmaceutical Co., Inc., Merck & Co., Inc., Pfizer Inc., Shionogi & Co., Ltd., VentiRx Pharmaceuticals, Inc., Faes Farma, S.A..
The perennial allergic rhinitis drug market is expected to register a CAGR of 5.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Perennial Allergic Rhinitis Drug Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Perennial Allergic Rhinitis Drug Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Perennial Allergic Rhinitis Drug Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Perennial Allergic Rhinitis Drug Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Perennial Allergic Rhinitis Drug Market Size & Forecast, 2020-2028
4.5.1 Perennial Allergic Rhinitis Drug Market Size and Y-o-Y Growth
4.5.2 Perennial Allergic Rhinitis Drug Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 APC-3000
5.2.2 Asapiprant
5.2.3 Bilastine
5.2.4 Desloratadine
5.2.5 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Clinic
6.2.2 Hospital
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Perennial Allergic Rhinitis Drug Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Perennial Allergic Rhinitis Drug Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 APC-3000
9.6.2 Asapiprant
9.6.3 Bilastine
9.6.4 Desloratadine
9.6.5 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Clinic
9.10.2 Hospital
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 APC-3000
10.6.2 Asapiprant
10.6.3 Bilastine
10.6.4 Desloratadine
10.6.5 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Clinic
10.10.2 Hospital
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 APC-3000
11.6.2 Asapiprant
11.6.3 Bilastine
11.6.4 Desloratadine
11.6.5 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Clinic
11.10.2 Hospital
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 APC-3000
12.6.2 Asapiprant
12.6.3 Bilastine
12.6.4 Desloratadine
12.6.5 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Clinic
12.10.2 Hospital
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 APC-3000
13.6.2 Asapiprant
13.6.3 Bilastine
13.6.4 Desloratadine
13.6.5 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Clinic
13.10.2 Hospital
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Perennial Allergic Rhinitis Drug Market: Competitive Dashboard
14.2 Global Perennial Allergic Rhinitis Drug Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Faes Farma, S.A.
14.3.2 Glenmark Pharmaceuticals Ltd.
14.3.3 Hisamitsu Pharmaceutical Co., Inc.
14.3.4 Merck & Co., Inc.
14.3.5 Pfizer Inc.
14.3.6 Shionogi & Co., Ltd.
14.3.7 VentiRx Pharmaceuticals, Inc.
14.3.8 Faes Farma, S.A.
